Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RACER53-X: Viltolarsen extension in DMD
NCT04768062Phase 3Active, not recruiting
- Sponsor
- NS Pharma, Inc.
- Start
- Apr 2021
- Primary completion
- Oct 2025
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of viltolarsen in Duchenne muscular dystrophy (DMD), sponsored by NS Pharma, Inc. Primary endpoint: Number of participants with treatment related Adverse Events up to 96 weeks. Started Apr 2021; status: active, not recruiting.
02
Drugs
viltolarsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04768062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768062.